Avalon GloboCare Announces Three-Way Material Transfer Agreement with Weill Cornell Medicine and Arbele Limited for Developme...
June 11 2020 - 9:00AM
Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global
developer of cell-based technologies and therapeutics, announced
today that it has entered into a three-way material transfer
agreement (MTA) with Weill Cornell Medicine in New York City and
the Company’s strategic partner, Arbele Limited.
With this agreement, Avalon GloboCare Corp. and Arbele Limited
intend to collaborate with Weill Cornell Medicine and co-develop
the standardized laboratory steps necessary to generate
clinical-grade CAR-T and CAR-NK cells for use in future human
clinical trials with Avalon’s first FLASH-CAR™ platform
candidate, AVA-011. This step, called process development, will
provide the bridge between Avalon’s benchtop research and the
bio-manufacturing processes to potentially deliver the
clinical-grade cellular immunotherapy product to patients.
“We are excited about this agreement to translate our cellular
therapy candidates into standardized, clinical-grade cell products
that could be used in future clinical trials. This step reflects
our dedication to establishing an infrastructure to develop our
cellular immunotherapy candidates and to maintain the highest
possible standards for generating clinical-grade cells for human
cancer trials,” stated David Jin, M.D., Ph.D., President and Chief
Executive Officer of Avalon GloboCare.
AVA-011 is a next generation cellular immunotherapy candidate
using Avalon’s FLASH-CAR™ that targets both CD19 and CD22
tumor antigens on cancer cells. Avalon has already successfully
completed pre-clinical research on AVA-011, including tumor
cytotoxicity studies. (See May 8, 2020 press release, ‘Avalon
GloboCare Advances Next Generation Cellular Immunotherapy with
FLASH-CAR™ Technology for Blood Cancers’)
Avalon’s next generation immune cell therapy using
FLASH-CAR™ technology is being co-developed with the Company’s
strategic partner Arbele Limited. The adaptable
FLASH-CAR™ platform may be used to create personalized cancer
cell therapy from a patient’s own cells, as well as off-the-shelf
cell therapy from a universal donor, expanding the reach of cancer
patients that could be treated.
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage,
vertically-integrated, leading CellTech bio-developer dedicated to
advancing and empowering innovative, transformative immune effector
cell therapy and exosome technology. Avalon also provides strategic
advisory and outsourcing services to facilitate and enhance its
clients' growth and development, as well as competitiveness in
healthcare and CellTech industry markets. Through its
subsidiary structure with unique integration of verticals from
innovative R&D to automated bioproduction and accelerated
clinical development, Avalon is establishing a leading role in the
fields of cellular immunotherapy (including CAR-T/NK), exosome
technology (ACTEXTM), and regenerative therapeutics. For more
information about Avalon GloboCare, please visit
www.avalon-globocare.com.
Forward-Looking Statements
Certain statements contained in this press release may
constitute "forward-looking statements." Forward-looking statements
provide current expectations of future events based on certain
assumptions and include any statement that does not directly relate
to any historical or current fact. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors as disclosed in our
filings with the Securities and Exchange Commission located at
their website (http://www.sec.gov). In addition to these factors,
actual future performance, outcomes, and results may differ
materially because of more general factors including (without
limitation) general industry and market conditions and growth
rates, economic conditions, and governmental and public policy
changes. The forward-looking statements included in this press
release represent the Company's views as of the date of this press
release and these views could change. However, while the Company
may elect to update these forward-looking statements at some point
in the future, the Company specifically disclaims any obligation to
do so. These forward-looking statements should not be relied upon
as representing the Company's views as of any date subsequent to
the date of the press release.
Contact Information: Avalon GloboCare Corp.4400 Route 9, Suite
3100Freehold, NJ 07728PR@Avalon-GloboCare.com
Investor Relations:Crescendo Communications, LLCTel: (212)
671-1020 Ext. 304avco@crescendo-ir.com
Avalon GloboCare (NASDAQ:AVCO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avalon GloboCare (NASDAQ:AVCO)
Historical Stock Chart
From Apr 2023 to Apr 2024